Trial · NCT07128641
Odronextamab in Low Tumor Volume Advanced FL
NCT07128641, Phase 2, Recruiting, Gottfried von Keudell, MD PhD
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Odronextamab in Low Tumor Volume Advanced FL. Trials, record NCT07128641. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07128641
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Odronextamab in Low Tumor Volume Advanced FL
- NCT number
- NCT07128641
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 35 participants, estimated
- Lead sponsor
- Gottfried von Keudell, MD PhD
- Conditions
- Follicular Lymphoma, Lymphoma
- Interventions
- Odronextamab
- First posted
- 2025-08-19
- Last updated
- 2026-03-13
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Complete Response Rate (CRR) | Assessed at baseline and every 3 cycles, treatment lasts for 6 cycles, each cycle is 21 days. | CRR is defined as the proportion of patients who accomplish a complete response (CR) as best response (CR rate) following treatment with odronextamab as per the revised Lugano criteria. |
| Secondary | Overall Response Rate (ORR) | Assessed at baseline and every 3 cycles, treatment lasts for 6 cycles, each cycle is 21 days. | ORR is defined as the proportion of participants that experience complete response (CR) or partial response (PR) during treatment as per the revised Lugano criteria. |
| Secondary | Median Progression Free Survival (PFS) | Every 9 weeks in the first 18 weeks, then every 3 months for 2 years, then annually through year 5. | Progression-Free Survival (PFS) based on Kaplan-Meier method is defined as the time from treatment start to either disease progression or death due to any cause (whichever occurs first). Participants alive without disease progression are censored at date of last disease evaluation. |
| Secondary | Median Overall Survival (OS) | Every 9 weeks in the first 18 weeks, then every 3 months for 2 years, then annually through year 15. | OS is Overall survival based on the Kaplan-Meier method is defined as the time from randomization to death. Participants alive are censored at the last date of contact (including lost-to-follow-up) or at the date of withdrawal of consent, if relevant. |
| Secondary | Median time to next treatment (TTNT) | Treatment lasts for 6 cycles, each cycle is 21 days. | TTNT is defined as is defined as the time from treatment start until date of initiation of next line of treatment. |
| Secondary | Median Duration of Response (DOR) | Every 9 weeks in the first 18 weeks, then every 3 months for 2 years, then annually through year 5. | The duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started), or death due to any cause. Participants without events reported are censored at the last disease evaluation. |
| Secondary | Median Duration of Complete Response (DOCR) | Every 9 weeks in the first 18 weeks, then every 3 months for 2 years, then annually through year 5. | The duration of overall CR is measured from the time measurement criteria are first met for CR until the first date that progressive disease is objectively documented, or death due to any cause. Participants without events reported are censored at the last disease evaluation. |
| Secondary | Rate of progression of disease within 24 months (POD24) | Up to 24 months. | Rate of POD24 is defined as the proportion of participants that the progress within 24 months, per revised Lugano criteria. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07128641
GET https://conductscience.org/api/trials/v1/NCT07128641/registered